Carmine Stengone, Contineum Therapeutics CEO
April 1, 2024 09:43 AM EDT
Financing
Startups

Con­tineum says it will seek $136M in IPO to back its mid-stage neu­ro drug

Kyle LaHucik

Senior Reporter

Con­tineum Ther­a­peu­tics has set a price range for its up­com­ing IPO and plans to sell 8.8 mil­lion shares be­tween $16 and $18 apiece.

Its ex­pect­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times